Accordingly, survival and tumor incidence curves upon CR were identical in Sirt3−/−; p53−/−; and p53−/− mice suggesting that both benefited (CR: Sirt3−/−; p53−/− vs. p53−/−p = 0.1 survival/CR: Sirt3−/−; p53−/− vs. p53−/−p = 0.2 tumor incidence). This evidence concerns the gene TP53 and neoplasm.